摘要
促红细胞生成素(erythropoietin,EPO)作为造血生长因子,可促进骨髓红细胞系统造血,还具有改善微循环、抗氧化、抑制炎症和免疫应急损伤等多重细胞保护功能,对新生儿的常见并发症具有重要防治意义。本文归纳了近五年来国内外上有关重组人红细胞生成素在早产儿领域的临床意义的阶段性研究进展,以供临床参考;同时也为未来开展相关基础试验与临床研究提供理论依据。
Erythropoietin(EPO) as a hematopoietic growth factor,can promote the hematopoiesis of bone marrow red blood cell system,improve microcirculation,antioxidation,inhibit inflammation,immune emergency damage and other multiple cell protection functions,which has important prevention and treatment significance for common complications of newborn.In this paper,the research progress at home and aboard on the clinical significance of recombinant human erythropoietin in the field of preterm infants in recent years was summarized for clinical reference,as well as theoretical basis for related basic experiments and clinical research in the future.
作者
傅晓燕
谢晓恬
FU Xiao-yan;XIE Xiao-tian(Department of Pediatrics,Luodian Hospital,Baoshan District,Shanghai 201908,China;Department of Pediatrics,Tongji Hospital of Tongji University,Shanghai 200065,China)
出处
《世界临床药物》
CAS
2020年第3期172-176,198,共6页
World Clinical Drug
基金
上海市宝山区科学技术委员会科研项目(16-E-23)。
